Skip to product information
1 of 2

Probio Myces

60 ct

Regular price $48.00 USD
Regular price Sale price $48.00 USD
Sale Sold out

Freeze-Dried Saccharomyces Boulardii

Probio Myces is a special freeze-dried strain of non-GMO Saccharomyces boulardii isolated from Litchi fruits. Probio Myces is dairy and lactose free and does not require refrigeration. Benefits of this source may include broader bioactivity and increased protection of the digestive mucosa. Also, it is this strain that has been most studied for its efficiency in the prevention of antibiotic-associated diarrheas, and as a general supplement for optimum gastrointestinal health.

Probio Myces May Be Helpful For

  • Diarrhea • Antibiotic-associated diarrhea
  • Traveler's diarrhea
  • Imbalanced GI mucosal immune function
  • Restoration of optimal GI microflora and mucosal health
  • Dysbiosis
  • Opportunistic bacterial overgrowth
  • Opportunistic Candida and other yeast overgrowths

The History of Saccharomyces Boulardii

Around the year 1920, Dr. Boulard made a unique discovery in Vietnam. He noticed that consuming a particular local drink could alleviate symptoms of diarrhea in villagers afflicted by an epidemic of cholera. This drink was made from tropical fruits such as lichee and mango. Dr. Boulard isolated an active agent from this drink, which proved to be a live yeast of natural origin, now known as Saccharomyces boulardii.

    Mechanisms of Action

    Today our understanding of the probiotic properties of S. boulardii includes the following:

    (a) Binding of enterohaemorrhagic E. coli and Salmonella;

    (b) Protection of the digestive mucosa;

    (c) Promotion of growth of lactic acid producing bacteria in the gut;

    (d) Protection against Clostridium difficile toxins; and

    (e) Stimulating effects on the intestinal mucosa and mucosal immunity.


    1. Bartlett J.G. 1992. Antibiotic-associated diarrhea. Clin Infect Dis; 15:573-81 2. Buts, J.P., P. Bernasconi, J.P. Vaerman, and C. Dive. 1990, Stimulation of secretory IgA and secretory component of immunoglobulin in

    2. Buts, J.P., P. Bernasconi, J.P. Vaerman, and C. Dive. 1990, Stimulation of secretory IgA and secretory component of immunoglobulin in small intestine of rats treated with Saccharomyces boulardii, Digest. Dis, Sci, 35:251-256.

    3. Buts, J.P., G. Corthier and H. Delmee. 1993. Saccharomyces boulardii for Clostridium difficile disease - associated enteropathies in infants. J. Pediatr. Gastroenterol. Nutr. 16: 419-425.

    4. Corthier, G., F. Lucas, S. Jouvest, and F. Castex. 1992. Effects of S. boulardii treatment on the activity of Clostridium difficile toxins in mouse digestive tract. Toxicon. 30 : 1583-1589.

    5. Czerucka D., S. Dahan, B. Mograbi, B. Rossi, and P. Rampal. 2000. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in entero pathogenic Escherichia coli infected T 84 cells. Infect Immun. 68 : 5998-6004.

    6. Dias, R.S., E.A. Bambirra, M.E. Silva, and J.R. Nicole. 1995. Protective effect of Saccharomyces boulardii against the cholera toxin in rats. Braz. J. Med. Biol. Res. 28 : 323-325.

    7. Elmer G.W., G. Corthier. 1990. Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventive agent in gnotobiotic mice, Can J. Microbiol. 37. 315-317.

    8. Elmer G.W., C.M. Surawicz, L.V. McFarland. 1996. Biotherapeutics agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 275; 870-876.

    9. Elmer, G.W., and L.V. Mc Farland. 1987. Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother.31: 129-131.

    10. Fuller, R. 1991. Probiotics in human medicine. Gut. 32 : 439-42.

    11. Jahn, H.L., R. Ullrich, T. Schneider, R.M. Liehr, H.L., et al. 1996. Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. Digestion. 57 :95-104.

    12. Pothoulakis, C., P. Kelly, M.A. Joshi, et al. 1993. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and entero-toxicity in rat ileum. J. Gastroenterology. 104 :1108-1115.

    13. Toothaker R.D., G.W. Elmer. 1984. Prevention of clindamycin-induced mortality in hamster by Saccharomyces boulardii, Can J. Microbiol. 32. 894 - 896.

    14. Zbinden R., E. Gônczi, and M. Allwegg. 1999. Inhibition of Saccharomyces boulardii (nom. Inv) on cell adhesion of S. typhimurium Yersinia ente- rocolitica. Microb. Ecol. Health Dis. 11: 158- 162.


    Recommended Use

    Take 2 capsules per day or as directed by your practitioner.